This Solicitation opportunity from Department Of Defense was posted on July 27, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
MOXIFLOXACIN HYDROCHLO
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
Moxifloxacin Hydrochloride Tablets, 400 mg in 30-count bottles, are procured under solicitation SPE2DP-26-T-4320 with a requirement for three bottles, delivered FOB destination within 20 days. The item is regulated by the FDA and must comply with the Medical Marking Standard No. 1, superseding MIL-STD-129, with all packaging and labeling adhering strictly to its specifications. Each unit must be sealed in commercial packaging capable of preventing damage and shipped in exterior containers suitable for safe transport via common carrier at the lowest rates. The product carries a non-extendable shelf life of 36 months and must be stored at controlled room temperature away from high humidity. The supplier must be identified by NDC number—either Teva Pharmaceuticals USA Inc. NDC 00093-7387-56 or Rising Pharma Holdings Inc. NDC 57237-0156-30—and all documentation must include bidder and manufacturer details for FDA referral via EBS. The unit of issue is bottle, and no variance in quantity is permitted. Packaging must meet MIL-STD-2073-1E standards, and delivery is to Fort Stewart, GA, with inspection and acceptance occurring at destination.
General Info
Agency
NAICS
Place of Performance
BLDG 1509 WEST 6TH STREET, FORT STEWART, GA, 31314-5185, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
MOXIFLOXACIN HYDROCHLORIDE TABLETS<(>,<)>
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
400 MG 30'S TABLETS PER BOTTLE. UNIT OF ISSUE "BOTTLE". STORE AT
CONTROLLED ROOM TEMPERATURE; AVOID HIGH HUMIDITY .. LABELING AND MARKING
MUST IN ACCORDANCE WITH MEDICAL MARKING STANDARD NO. 1A DATED 4 FEBRUARY
2013.
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description. 1 BT = 30 EA RS020: Shelf-life requirement RS001 for a TYPE I (CODE Q) item with a shelf life of 36 months (non-extendable) applies to this item.
APPLICABLE TO ALL MEDICAL ACQUISITIONS:
PACKAGING AND PACKING SHALL BE COMMERCIAL AS
SPECIFIED IN THE PROCUREMENT DOCUMENT.
EACH COMPLETE UNIT SHALL BE PROPERLY PACKAGED
IN A SUITABLE SEALED UNIT CONTAINER CAPABLE
OF PROTECTING THE CONTENTS FROM DAMAGE AND/OR
BREAKAGE.
UNITS SHALL BE PACKED IN SUITABLE COMMERCIAL
EXTERIOR (SHIPPING) CONTAINERS (EXPORT WHEN
NECESSARY) WHICH SHALL INSURE ACCEPTANCE AND
SAFE DELIVERY BY COMMON OR OTHER CARRIER, AT
THE LOWEST RATE, TO POINT OF DELIVERY CALLED
FOR IN THE CONTRACT OR ORDER.
MATERIAL MUST BE MARKED IAW MEDICAL MARKING
STANDARD NO. 1. THIS SUPERCEDES ALL REFERENCES
TO MIL-STD-129.
COPIES OF MEDICAL MARKING STANDARD NO. 1
(MMS NO. 1) MAY BE OBTAINED BY CONTACTING DLA
TROOP SUPPORT VIA EMAIL TO fssb@dla.mil. MMS NO. 1 IS ALSO AVAILABLE ONLINE AT: https://www.dla.mil/Logistics-Operations/Packaging/
SPE2DP-26-T-4320
SECTION B
RD003, COVERED DEFENSE INFORMATION POTENTIALLY APPLIES
SHALL BE MARKED IAW THE LATEST EDITION OF
THE MEDICAL MARKING STANDARD NO. 1.
MMS NO. 1 IS AVAILABLE ONLINE AT:
https://www.dla.mil/Logistics-Operations/Packaging/
TEVA PHARMACEUTICALS USA, INC. 3V8D7 P/N NDC00093-7387-56 RISING PHARMA HOLDINGS, INC. 8FG82 P/N NDC57237-0156-30
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7017626093 0001 BT 3.000
NSN/MATERIAL:6505015034772
DELIVERY (IN DAYS):0020
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA MIL-STD-2073-1E
SPECIAL NSN/Part Number: 6505-01-503-4772 Quantity: 3 BT Purchase Request: 7017626093QTY: 3 Delivery: 20 days ADO
More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS